Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | GNPAT | O15228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331855 | 0.87 | HIF1A (0.32) | ENPEPHIF1APTGS1GSTK1CA1 | |
| SCHEMBL3326521 | 0.85 | PTGS1 (0.37) | ENPEPHIF1APTGS1GSTK1CA1 | |
| SCHEMBL13301149 | 0.81 | FNTA (0.39) | ENPEPGNPAT | |
| SCHEMBL2992278 | 0.81 | KDM4E (0.47) | ENPEPANPEPHIF1ACA1CA2 | |
| SCHEMBL3328021 | 0.80 | SIRT6 (0.40) | — | |
| SCHEMBL929799 | 0.78 | FOLH1 (0.44) | PTGS1GSTK1CA2GNPAT | |
| SCHEMBL929798 | 0.78 | FOLH1 (0.44) | PTGS1GSTK1CA2GNPAT | |
| SCHEMBL8765134 | 0.78 | FOLH1 (0.44) | PTGS1GSTK1CA2GNPAT | |
| SCHEMBL21980976 | 0.73 | HIF1A (0.33) | ENPEPANPEPHIF1ACA1CA2 | |
| SCHEMBL13301147 | 0.72 | NOD1 (0.43) | PTGS1GSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095467-B1 | ANTIBODY-ENZYME CONJUGATE | VENTANA MED SYST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2963011-B1 | MOLECULAR CONJUGATE | VENTANA MED SYST INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3095467-A1 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160195540-A1 | Molecular Conjugate | VENTANA MED SYST INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-9310373-B2 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2963011-A1 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140205995-A1 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20100136652-A1 | Molecular Conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100136652-A1 | Molecular Conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2010-06-03 | — | — | US | disclosed |
| WO-2007062177-A2 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195540-A1 | Molecular Conjugate | CA12, FCGR2A, CA14 | ENPEP 24/4885ANPEP 112/4885HIF1A 3349/4885 |
| US-20100136652-A1 | Molecular Conjugate | CA12, FCGR2A, CA14 | ENPEP 24/4885ANPEP 112/4885HIF1A 3349/4885 |
| US-20070117153-A1 | Molecular conjugate | CA12, FCGR2A, CA14 | ENPEP 24/4885ANPEP 112/4885HIF1A 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.